公开(公告)号：EP3335703A1

公开(公告)日：2018-06-20

申请号：EP16204721.1

申请日：2016-12-16

申请人： Hexal AG

发明人： BORN, Max ,  FISCHER-DAUT, Diana ,  PUZIK, Andreas

IPC分类号： A61K9/20 ,  A61K31/4162 ,  A61P3/10

CPC分类号： A61K9/2018 ,  A61K9/2054 ,  A61K31/4162

摘要： The present invention relates to a pharmaceutical composition comprising omarigliptin or a pharmaceutically acceptable salt thereof and less than 75% by weight of neutral excipients, a process for preparing the pharmaceutical composition and its use in the treatment of type 2 diabetes mellitus.

公开(公告)号：EP3335702A1

公开(公告)日：2018-06-20

申请号：EP16204720.3

申请日：2016-12-16

申请人： Hexal AG

发明人： BORN, Max ,  FISCHER-DAUT, Diana ,  PUZIK, Andreas

IPC分类号： A61K9/20 ,  A61K31/4162 ,  A61P3/10

CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/4162

摘要： The present invention relates to a pharmaceutical composition comprising omarigliptin and at least one pharmaceutically acceptable excipient, wherein the omarigliptin is in the form of a pharmaceutically acceptable acid addition salt and its use in the treatment of type-2 diabetes mellitus.

公开(公告)号：EP3335701A1

公开(公告)日：2018-06-20

申请号：EP16204717.9

申请日：2016-12-16

申请人： Hexal AG

发明人： BORN, Max ,  FISCHER-DAUT, Diana ,  PUZIK, Andreas

IPC分类号： A61K9/20 ,  A61K9/48 ,  A61K31/4162

CPC分类号： A61K9/0095 ,  A61K9/2059 ,  A61K9/4866 ,  A61K31/4162

摘要： The present invention relates to a pharmaceutical composition comprising omarigliptin or a pharmaceutically acceptable salt thereof and a diluent, wherein the diluent comprises a reducing sugar, a process for preparing the pharmaceutical composition and its use in the treatment of type 2 diabetes mellitus.